While there were certainly logical reasons for breaking up the two companies, there was also plenty of doubt because bigger rivals such as Johnson & Johnson (JNJ) had resisted doing the same thing, even though some investors demanded it. In fact, Johnson & Johnson has actually gotten bigger after its acquisition of Synthes, which has now brought JNJ plenty of growth.
For Abbott, however, the situation is far different. The post-split era brought with it plenty of expectations that the remaining portion of Abbott, which consists of the devices business, would be stronger and leaner. So far, investors have only seen the latter. That's not to suggest that Abbott is struggling. But investors haven't been content with low single-digit growth, either.
A Broadly Positive First QuarterRevenue was up 1.8% year over year to $5.38 billion, slightly below consensus estimates of $5.42 billion. While the soft sales were adversely impacted by a 1.7% currency rate, not much can be said, however, about Abbott's sequential performance, because the company's fourth-quarter report included portions of the spun-off AbbVie business.
As has been the case for some time, Abbott's Nutritional business, which posted a 14% surge in emerging markets, was again the primary growth-driver this quarter. Likewise, the Diagnostics division did well -- growing more than 4% year over year. Management said that the better-than-expected performance was due to strong growth in the company's Point of Care Diagnostic and Core Laboratory products. Unfortunately, though, these solid performances were negated by poor results in Abbott's Medical Devices business, which declined by almost 5% year over year (-3% operationally). This is a concern because the devices business is Abbott's largest division. Not to suggest that management is incapable of growing the business, but weak device sales have also been an issue for larger names like Johnson & Johnson. In fact, this was the reason Johnson & Johnson went after Synthes. While Johnson & Johnson is now posting double-digit devices growth both domestic and internationally, not much of that growth is organic.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV